19 reports

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Antifungal
  • Blood Disease
  • Oncology
  • Therapy
  • Bristol-Myers Squibb Company
  • MEPOLIZUMAB - DRUG PROFILE

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Digestive System Disorder
  • Oncology
  • United States
  • Product Initiative
  • trials that will further assess treatment of subsequent asthma attacks in mepolizumab-naive as well as previously-treated patients.
  • MEPOLIZUMAB - DRUG PROFILE

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Chronic Disease
  • Oncology
  • Respiratory Disease
  • United States
  • Product Initiative
  • trials that will further assess treatment of subsequent asthma attacks in mepolizumab-naive as well as previously-treated patients.
  • MEPOLIZUMAB - DRUG PROFILE

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Blood Disease
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • United States

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Oncology
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • trials that will further assess treatment of subsequent asthma attacks in mepolizumab-naive as well as previously-treated patients.
  • MEPOLIZUMAB - DRUG PROFILE

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Monoclonal Antibody
  • Oncology
  • United States
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Monoclonal Antibody
  • Oncology
  • Respiratory Disease
  • United States
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

Rituximab was well tolerated, and most adverse drug reactions were grade ##-## in severity.

  • Monoclonal Antibody
  • Oncology
  • Therapy
  • United States
  • Product Initiative

DRUG HYPERSENSITIVITY REACTIONS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2019* PROMINENT DRUGS DRUG HYPERSENSITIVITY REACTIONS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2019*

  • Clinical Trial
  • Oncology
  • Therapy
  • World
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ##, ## and ## respectively.

  • Monoclonal Antibody
  • Oncology
  • Therapy
  • United States
  • Product Initiative
  • TRIALS THAT WILL FURTHER ASSESS TREATMENT OF SUBSEQUENT ASTHMA ATTACKS IN MEPOLIZUMAB-NAIVE AS WELL AS PREVIOUSLY-TREATED PATIENTS.
  • MEPOLIZUMAB - DRUG PROFILE

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Oncology
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Drug/ Molecule refers to Primary Intervention only. ##.

  • Antifungal
  • Monoclonal Antibody
  • Oncology
  • Pharmaceutical
  • World
  • MEPOLIZUMAB - DRUG PROFILE

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Allergy Drug
  • Dermatological Condition
  • Oncology
  • United States
  • Product Initiative
  • DEXAMETHASONE - DRUG PROFILE
  • DEXAMETHASONE - DRUG PROFILE

The drug candidate targets P/ neurokinin ## (NK##) receptors.

  • Antifungal
  • Oncology
  • United States
  • Product Initiative
  • Helsinn Group
  • DEXAMETHASONE - DRUG PROFILE

The drug candidate targets P/ neurokinin ## (NK##) receptors.

  • Antifungal
  • Oncology
  • United States
  • Product Initiative
  • Helsinn Group

The FACT ## trial is evaluating the safety and efficacy of Genentech s drugs, Herceptinand Perjeta, and chemotherapy, in early stage breast cancer patients selected with Celcuity s CELx HSF Test.

  • Clinical Trial
  • Diagnostics
  • Infectious Disease
  • Oncology
  • Grifols, S.A.
  • MEPOLIZUMAB - DRUG PROFILE

This explains the need for a high drug dose of IXF-## as supported by the findings of the recently published post-hoc analysis.

  • Monoclonal Antibody
  • Oncology
  • Therapy
  • United States
  • Product Initiative

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Infectious Disease
  • Oncology
  • United States
  • SCYNEXIS, Inc.
  • MEPOLIZUMAB - DRUG PROFILE
  • MEPOLIZUMAB - DRUG PROFILE

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Antifungal
  • Clinical Trial
  • Oncology
  • United States
  • AstraZeneca PLC